These findings were compared with a study from our group using the same methodology in patients with advanced disease where ESR1 mutations were identified in 25% (n = 32) of cases with visceral metastasis of ER+ breast cancer resistant to ET (8). This evidence concerns the gene ESR1 and breast carcinoma.